Matinas BioPharma Holdings, Inc. — Form 8-K
Filed September 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On August 31, 2026, Matinas BioPharma received notice of non-compliance with NYSE American listing standards. The company has stockholders' equity of $1.8 million (below the required $2.0 million minimum) and has reported losses in five consecutive fiscal years. The NYSE American granted a plan period through October 2, 2027 to regain compliance; failure to do so will trigger delisting proceedings. Shares remain listed during this period with a .BC non-compliance indicator.
Why this rating
Delisting threat existentially challenges a $4.5M market-cap company; non-compliance on equity/losses is near-terminal for micro-cap biotech with no disclosed near-term revenue.
Tradability signal
NO TRADE
No trade: price $0.18 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.19 ▲ 3.79% | at our read · unknown $0.18 | +10 min · unknown $0.18 ▲ 0.00% | +30 min · unknown $0.18 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved -3.65% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.